Gilde Healthcare
Gilde Healthcare, established in 1982 and headquartered in Utrecht, Netherlands, is a leading venture capital firm specializing in the healthcare sector. With over €800 million under management, the firm invests in digital health, diagnostics, medical devices, therapeutics, and healthcare services across Europe and North America. Gilde focuses on growth capital and buyout opportunities, typically investing between €1 million and €40 million per transaction, with a preference for majority or significant minority stakes. The firm seeks to be the lead investor and take a board seat, aiming to exit through IPOs, strategic sales, or private placements. Gilde's portfolio spans various healthcare sub-sectors, with a particular emphasis on cardiology, oncology, and women's health.
GT Medical Technologies
Series D in 2025
GT Medical Technologies, Inc. is a medical device company based in Tempe, Arizona, dedicated to improving the lives of patients with brain tumors. Founded in 2017, the company has developed an innovative treatment approach through its flagship product, GammaTile, which combines a biocompatible, conformable collagen matrix with brachytherapy radiation seeds. This technology is designed to address the limitations of existing treatments for recurrent brain tumors, providing a bioresorbable solution that enhances treatment efficacy. GammaTile is protected by multiple patents and has the potential to benefit a significant patient population, with an estimated 176,000 patients diagnosed annually in the United States. To date, clinical trials at Barrow Neurological Institute have demonstrated promising outcomes, with significant clinical improvements observed in patients treated with this novel device.
GT Medical Technologies
Series C in 2023
GT Medical Technologies, Inc. is a medical device company based in Tempe, Arizona, dedicated to improving the lives of patients with brain tumors. Founded in 2017, the company has developed an innovative treatment approach through its flagship product, GammaTile, which combines a biocompatible, conformable collagen matrix with brachytherapy radiation seeds. This technology is designed to address the limitations of existing treatments for recurrent brain tumors, providing a bioresorbable solution that enhances treatment efficacy. GammaTile is protected by multiple patents and has the potential to benefit a significant patient population, with an estimated 176,000 patients diagnosed annually in the United States. To date, clinical trials at Barrow Neurological Institute have demonstrated promising outcomes, with significant clinical improvements observed in patients treated with this novel device.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.